The life sciences sector contributed £43.3 billion ($52.6 billion) to the UK economy in 2021 through production of goods and services, with pharma manufacturing responsible for a majority of £19.2 billion.
So says analysis from accounting giant PwC in its Life Sciences Future50 report, which identifies 50 UK firms seeking to tackle challenging problems in the human health and science space.
"It is critical that we boost the availability of late-stage funding and infrastructure capacity to enable these companies to flourish"The sector has seen strong growth since before the pandemic in 2019, with a 17.6% rise from £36.9 billion in gross value added (GVA) in two years, the analysis found.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze